Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Exscientia Ltd ADR (NQ: EXAI )

4.820 +0.090 (+1.90%)
Streaming Delayed Price Updated: 12:46 PM EDT, May 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Exscientia Ltd ADR

< Previous 1 2 3 4 Next >
The 3 Best Machine Learning Stocks to Quadruple Your Money by 2035
One of the hottest investment trends to jump on at the moment is machine learning stocks to buy. Here are three. 
Via InvestorPlace
EXAI Stock Earnings: Exscientia Beats EPS, Misses Revenue for Q1 2024
EXAI stock results show that Exscientia beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
All 7 Artificial Intelligence (AI) Categories Reversed Direction This Week
All 7 of the AI categories we track were up 2.9%, on average, this week. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Exscientia Earnings Preview
Via Benzinga
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Via Benzinga
The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD
The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
Exposures Glyphosate
Six Of Seven AI Stock Categories Increased This Week
All but one of the 7 artificial intelligence stock categories that I analyze weekly increased in value this week. But two categories are still down MTD, suggesting that the surge in the artificial... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
EXAI Stock Earnings: Exscientia Misses EPS, Misses Revenue for Q4 2023
EXAI stock results show that Exscientia missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 21, 2024
Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is expected to report quarterly earnings at $0.02 per share on revenue of $16.47 million. 
Via Benzinga
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy. 
Via InvestorPlace
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI Drug Hunter Firm Exscientia Fires Its CEO Over 'Inappropriate' Relationships with Two Employees
Exscientia terminates CEO Andrew Hopkins over inappropriate relationships with employees. Interim CEO appointed. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why IPG Photonics Shares Are Trading Lower By Around 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of IPG Photonics Corporation (NASDAQ: IPGP) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued soft first-quarter guidance. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth reading about for Monday morning! 
Via InvestorPlace
Why WD-40 Shares Are Trading Higher By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of WD-40 Company (NASDAQ: WDFC) rose sharply during Wednesday’s session after the company reported better-than-expected first-quarter results. 
Via Benzinga
Why Applied Therapeutics Shares Are Trading Lower By Over 35%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Applied Therapeutics, Inc. 
Via Benzinga
M&A Watch: 3 Drug Maker Stocks That Could Be Acquired in 2024
Lower interest rates and the low valuation of many biotech stocks are likely to result in many drug maker stocks being acquired in 2024. 
Via InvestorPlace
Top Picks 2024: Exscientia Plc
Founded in 2012 and based in Oxford, England, Exscientia Plc is using Artificial Intelligence to develop new medicines and is attracting high-quality partners. It has a rapidly growing pipeline of more... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
AI-Focused Drug Discovery Stocks Index Up 26% In December
With the promise of lower costs and shorter development timelines, AI-enabled drug discovery holds massive potential to increase the accessibility of drugs and to treat presently incurable conditions. 
Via Talk Markets
AI-Focused Drug Discovery Stocks Index Up 10.6% Last Week
A new study concludes that the AI method of drug discovery is up to 250 times more efficient than the traditional method. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
The 10 Stocks Using AI To Develop New Drugs Were Up 4%, On Average, Last Week
If, as Morgan Stanley postulates, a $50 billion AI drug discovery revolution is underway, here are 10 publicly-traded micro- and small-cap clinical stage pharma companies that are embracing AI to... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Looking for the Next Big Thing? Add This AI Biotech to Your Watch List Right Now
Exscientia has the potential to be a star collaborator and a profitable drug developer, too. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.